Public Health Impact of Pneumococcal Conjugate Vaccine in India: A Review of Available Evidence
DOI:
https://doi.org/10.17140/phoj.11.01.145Keywords:
Pneumonia, Pneumococcal Conjugate Vaccine, UIP, Public Health, Impact, IndiaAbstract
Pneumococcal disease is a major cause of morbidity and mortality in children less than five years of age with low- and middle-income countries having the highest incidences. It is caused by Streptococcus pneumoniae and it is presented as pneumonia, meningitis, sepsis, and otitis media, with pneumonia contributing a significant percentage of causes of childhood mortality that can be prevented. The pneumococcal disease burden in India is grossly disproportional as it has a large birth population, socioeconomic disparity, malnutrition, unpredictable exposure to environmental threats, and inconsistent access to quality healthcare. Although significant progress has been made in terms of child survival, pneumonia remains a significant cause of under-five mortality. India rolled out PCV in its Universal Immunization Programme in a phased way, where it started to introduce in high-burden states starting with the World Health Organization’s strong evidence and recommendations in 2017.
The current narrative review is a synthesis of the available evidence from the published literature, surveillance reports, program evaluations, and modeling studies to determine the public health implications of PCV implementation in India. The review is concerned with the effectiveness of vaccines against pneumonia and invasive pneumococcal disease, child survival, economic effects, and difficulties in implementation.
The available evidence suggests that PCV introduction in India has been connected to the decrease in severe and radiologically verified pneumonia hospitalization, decrease in the vaccine-type pneumococcal isolates, and possible indirect advantages because of herd protection. Averted cases, deaths, and healthcare expenses are modeled at a nationwide level to be substantial and have a scale-up type.
PCV introduction is starting to deliver significant public health impact in India especially in reducing the morbidity associated with pneumonia. Financial permanence, enhanced surveillance and fair implementation are needed in order to maximize long term effects on child health and survival
References
Perdrizet, J., Rozenbaum, M. H., & Heffler, M. J. (2024). Pediatric pneumococcal vaccine percep-tions. Infectious Diseases and Therapy, 13(9), 2017.
Ghia, C., Horn, E. K., Rambhad, G., Perdrizet, J., Chitale, R., & Wasserman, M. (2021). Economic impact of pneumococcal vaccines in India. Infec-tious Diseases and Therapy, 10(4), 2271.
Vo, N. X., Pham, H., Bui, U. M., Ho, H. T., & Bui, T. T. (2024). Cost-effectiveness of pneumococcal vaccines. Healthcare, 12(19), 1950.
Dai, Q., Dong, Y., Wu, J., & Peng, Q. (2025). Effi-cacy and safety of pneumococcal vaccines. Fron-tiers in Pediatrics, 13, 1652946.
Global Pneumococcal Disease and Policies for Control. (2014). Pneumonia overview. Pneumo-nia, 3(1), 222.
Kolhapure, S., Yewale, V., Agrawal, A., Krish-nappa, P., & Soumahoro, L. (2021). Pneumococ-cal disease burden in Southeast Asia. Journal of Infection in Developing Countries, 15(6), 749.
Awasthi, S., Kohli, N., Agarwal, M., et al. (2022). Effectiveness of PCV13 in India. PLoS ONE, 17(12).
O’Brien, K. L., Wolfson, L. J., Watt, J., et al. (2009). Global burden of pneumococcal disease. The Lancet, 374, 893.
Jayaraman, Y., Veeraraghavan, B., Kumar, C. P. G., et al. (2018). Bacterial meningitis burden in India. PLoS ONE, 13(5).
Varghese, R., Veeraraghavan, B., Jeyaraman, Y., et al. (2019). PCV rollout in India. Indian Journal of Medical Microbiology, 37(2), 141.
Reyburn, R., Tsatsaronis, A., Mollendorf, C. von, et al. (2023). Impact of PCV vaccines on pneumo-nia. Journal of Global Health, 13.
Rafiqullah, I., Varghese, R., Hellmann, K., et al. (2024). Pneumococcal genomics changes. Micro-bial Genomics, 10(2).
Lister, A., Dombay, E., Cleary, D., & Clarke, S. C. (2023). Serotype prevalence in Southeast Asia. medRxiv.
Warren, S., Barmpouni, M., Kossyvaki, V., et al. (2023). Economic impact of vaccine switching. Vaccines, 11(8), 1369.
Prasad, N., Stoecker, C., Xing, W., et al. (2023). Cost-effectiveness of PCV15 in the USA. Vaccine, 41(18), 2914.
Weeks, R., Dhaliwal, B. K., Huber, J., et al. (2024). Policy perspectives on PCV. medRxiv.
Wilson, M., Lucas, A. O., Mendes, D., et al. (2023). Cost-effectiveness of higher-valency PCV. Vac-cines, 11(7), 1168.
Chen, S., Rodewald, L. E., Du, A. H., & Tang, S. (2024). National immunization programs. Infec-tious Diseases of Poverty, 13(1).
Apte, A., Dayma, G., Naziat, H., et al. (2021). Pneumococcal carriage in South Asia. Journal of Global Health, 11.
Kartasasmita, C. B., Hadinegoro, S. R., Kurniati, N., et al. (2020). Epidemiology of pneumococcus in Indonesia. Infectious Diseases and Therapy, 9(4), 723.
Flasche, S., Lipsitch, M., Ojal, J., & Pinsent, A. (2020). Transmission modelling of pneumococ-cus. BMC Medicine, 18(1).
Griffin, M. R., Mitchel, E. F., Moore, M. R., et al. (2014). Decline in pneumonia hospitalizations. MMWR, 63(44), 995.
Murugan, R., VanderEnde, K., Dhawan, V., et al. (2022). Measles and rubella elimination in India. MMWR, 71(50), 1569.
Elemuwa, U. G., Ehijie, E., Elemuwa, C. O., et al. (2024). Pentavalent vaccine safety. medRxiv.
Kjær, S. K., Dehlendorff, C., Belmonte, F., & Baan-drup, L. (2021). HPV vaccine effectiveness. JNCI, 113(10), 1329.
Kumar, P., Ray, A., Kumari, A., et al. (2025). PCV introduction in India. Vaccines, 13(4), 432.
Krishnamoorthy, Y., Eliyas, S. K., Nair, N. P., et al. (2018). Cost-effectiveness of PCV in India. Vac-cine, 37(4), 623.
Smith-Vaughan, H., Temple, B., Dai, V. T. T., et al. (2022). PCV schedules in infants. Lancet Regional Health, 32, 100651.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Public Health - Open Journal (PHOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
